1. de Kock L, Wu MK, Foulkes WD. Ten years of DICER1 mutations:
provenance, distribution, and associated phenotypes. Hum Mutat
2019;40:1939-1953.
2. Stewart DR, Best AF, Williams GM, et al. Neoplasm risk among
individuals with a pathogenic germline variant in DICER1. J Clin Oncol
2019;37:668-676.
3. Hill DA, Ivanovich J, Priest JR, et al. DICER1 mutations in
familial pleuropulmonary blastoma. Science 2009;325:965.
4. Brenneman M, Field A, Yang J, et al. Temporal order of RNase
IIIb and loss-of-function mutations during development determines
phenotype in pleuropulmonary blastoma / DICER1 syndrome: a unique
variant of the two-hit tumor suppression model. F1000Res 2015;4:214.
5. Seki M, Yoshida K, Shiraishi Y, et al. Biallelic DICER1
mutations in sporadic pleuropulmonary blastoma. Cancer Res
2014;74:2742-2749.
6. Schultz KA, Stewart DR, Kamihara J, et al. DICER1 tumor
predisposition. In: Adam MP, Feldman J, Mirzaa GM, et al. (eds.).
GeneReviews®. Seattle: University of Washington; 2014.
7. Schultz KAP, Harris A, Messinger Y, et al. Ovarian tumors
related to intronic mutations in DICER1: a report from the international
ovarian and testicular stromal tumor registry. Fam Cancer
2016;15:105-110.
8. Verrier F, Dubois d’Enghien C, Gauthier-Villars M, et al.Mutiple DICER1-related lesions associated with a germline deep intronic
mutation. Pediatr Blood Cancer 2018;65:e27005.
9. Fraire CR, Mallinger PR, Hatton JN, et al. Intronic germline
DICER1 variants in patients with Sertoli-Leydig cell tumor. JCO Precis
Oncol 2023;7:e2300189.
10. Apellaniz-Ruiz M, Sabbaghian N, Chong AL, et al.Reclassification of two germline DICER1 splicing variants leads to
DICER1 syndrome diagnosis. Fam Cancer 2023;22:487-493.
11. de Kock L, Wang YC, Revil T, et al. High-sensitivity
sequencing reveals multi-organ somatic mosaicism causing DICER1
syndrome. J Med Genet 2016;53:43-52.
12. Terraf P, Pareja F, Brown DN, et al. Comprehensive assessment
of germline pathogenic variant detection in tumor-only sequencing. Ann
Oncol 2022;33:426-433.
13. Kommoss FKF, Stichel D, Mora J, et al. Clinicopathologic and
molecular analysis of embryonal rhabdomyosarcoma of the genitourinary
tract: evidence for a distinct DICER1-associated subgroup. Mod Pathol
2021;34:1558-1569.
14. Cross SF, Arbuckle S, Priest JR, Marshall G, Charles A, Dalla Pozza
L. Familial pleuropulmonary blastoma in Australia. Pediatr Blood
Cancer 2010;55:1417-1419.
15. Doros L, Yang J, Dehner L, et al. DICER1 mutations in
embryonal rhabdomyosarcomas from children with and without familial
PPB-tumor predisposition syndrome. Pediatr Blood Cancer 2012;59:558-560.
16. Miyama Y, Makise N, Miyakawa J, Kume H, Fukayama M, Ushiku T.An autopsy case of prostatic rhabdomyosarcoma with DICER1 hotspot
mutation. Pathol Int 2021;71:102-108.
17. Eckstein M, Agaimy A, Woenckhaus J, et al. DICER1
mutation-positive giant botryoid fibroepithelial polyp of the urinary
bladder mimicking embryonal rhabdomyosarcoma. Hum Pathol 2019;84:1-7.
18. Schultz KAP, Williams GM, Kamihara J, et al. DICER1 and
associated conditions: identification of at-risk individuals and
recommended surveillance strategies. Clin Cancer Res 2018;24:2251-2261.
19. Bakhuizen JJ, Hanson H, van der Tuin K, et al. Surveillance
recommendations for DICER1 pathogenic variant carriers: a report from
the SIOPE Host Genome Working Group and CanGene-CanVar Clinical
Guideline Working Group. Fam Cancer 2021;20:337-348.
20. Faure A, Atkinson J, Bouty A, et al. DICER1 pleuropulmonary
blastoma familial tumour predisposition syndrome: what the paediatric
urologist needs to know. J Pediatr Urol 2016;12:5-10.